Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Farago

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2019
Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking HistoryIbiayi Dagogo-Jack, Hayley Robinson, Mari Mino-Kenudson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2024
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS OutcomesCatherine B Meador, Subba R Digumarthy, Beow Y Yeap, et al.
JCO Precision Oncology|April 30, 2019
Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed <i>EGFR</i> Mutant Non-Small-Cell Lung CancerMeghan J Mooradian, Zofia Piotrowska, Benjamin J Drapkin, et al.
Immunity|September 6, 2015
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell ResponsesNikhil S Joshi, Elliot H Akama-Garren, Yisi Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation DiversityIbiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.
Cancer Research Communications|June 9, 2025
Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World DataLang Ho Lee, Xin Xu, Thanos Mourikis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032Neal Ready, Anna F Farago, Filippo de Braud, et al.
Science Advances|May 13, 2022
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancerMarcello Stanzione, Jun Zhong, Edmond Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
The Oncologist|July 23, 2020
The Art of Oncology: COVID-19 EraKerry L Reynolds, Samuel J Klempner, Aparna Parikh, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2019
Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking HistoryIbiayi Dagogo-Jack, Hayley Robinson, Mari Mino-Kenudson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2024
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS OutcomesCatherine B Meador, Subba R Digumarthy, Beow Y Yeap, et al.
JCO Precision Oncology|April 30, 2019
Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed <i>EGFR</i> Mutant Non-Small-Cell Lung CancerMeghan J Mooradian, Zofia Piotrowska, Benjamin J Drapkin, et al.
Immunity|September 6, 2015
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell ResponsesNikhil S Joshi, Elliot H Akama-Garren, Yisi Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation DiversityIbiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.
Cancer Research Communications|June 9, 2025
Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World DataLang Ho Lee, Xin Xu, Thanos Mourikis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032Neal Ready, Anna F Farago, Filippo de Braud, et al.
Science Advances|May 13, 2022
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancerMarcello Stanzione, Jun Zhong, Edmond Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2019
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY StudyDaniel Morgensztern, Benjamin Besse, Laurent Greillier, et al.
The Oncologist|July 23, 2020
The Art of Oncology: COVID-19 EraKerry L Reynolds, Samuel J Klempner, Aparna Parikh, et al.
Pageof 7